

**Biocon Limited**

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/45

July 29, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen”**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH
UMAKANT
SHANOE

Digitally signed
by RAJESH
UMAKANT
SHANOE
Date: 2026.07.29
08:26:51 +05'30'

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen

Bengaluru, Karnataka, India, July 29, 2026

Biocon Limited's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek® (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada. [Health Canada previously granted Notice of Compliance](#) for Yesintek® (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek® I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025.

The availability of the Yesintek® Autoinjector provides patients with an option that the originator product does not offer in Canada. The new format will allow customized treatment approaches across care settings and patient needs.

Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients (6-17 years of age), active psoriatic arthritis in adults, moderately to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affect thousands of Canadians.

This approval further strengthens Biocon's portfolio of immunology products in Canada and reaffirms the company's commitment to increasing patient access to affordable medicines around the world.

– Company Spokesperson